Cytek Biosciences (CTKB) Cash & Equivalents (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Cash & Equivalents data on file, last reported at $65.7 million in Q1 2026.

• Quarterly Cash & Equivalents fell 31.06% year-over-year to $65.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $65.7 million (down 31.06% YoY) and the FY2025 annual result came in at $90.9 million, down 7.97% from the prior year.
• Cash & Equivalents slipped to $65.7 million in Q1 2026, from $90.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $362.5 million in Q1 2022 to a low of $65.7 million in Q1 2026.
• A 5-year average of $173.4 million and a median of $162.3 million in 2024 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2022 — Cash & Equivalents jumped 112.28% — and 2023, when it tumbled 64.28%.
• Tracing CTKB's Cash & Equivalents over 5 years: stood at $296.6 million in 2022, then sank by 43.59% to $167.3 million in 2023, then slumped by 40.99% to $98.7 million in 2024, then fell by 7.97% to $90.9 million in 2025, then fell by 27.69% to $65.7 million in 2026.
• The last three Cash & Equivalents figures came in at $65.7 million (Q1 2026), $90.9 million (Q4 2025), and $93.3 million (Q3 2025), per Business Quant data.